de Braud F - Search Results

1

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.

Gevorgyan A, Bregni G, Galli G, Zanardi E, de Braud F, Di Cosimo S. Gevorgyan A, et al. Among authors: de braud f. Breast Care (Basel). 2016 Dec;11(6):424-426. doi: 10.1159/000453572. Epub 2016 Dec 9. Breast Care (Basel). 2016. PMID: 28228710 Free PMC article.

2

Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.

Di Cosimo S, Serpico D, Porcu L, Molino L, Fanetti G, Torri V, de Braud F. Di Cosimo S, et al. Among authors: de braud f. Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174. doi: 10.1016/j.clon.2013.11.028. Epub 2013 Dec 22. Clin Oncol (R Coll Radiol). 2014. PMID: 24368057 No abstract available.

3

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Pietrantonio F, et al. Among authors: de braud f. Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29. Ann Oncol. 2014. PMID: 24379162 Free article. Clinical Trial.

4

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Martinetti A, et al. Among authors: de braud f. Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753. Cancers (Basel). 2014. PMID: 25256831 Free PMC article.

5

Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients.

Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, Galli G, De Braud F, Saravia D, Salvioni R. Procopio G, et al. Among authors: de braud f. Oncology. 2015;88(3):133-8. doi: 10.1159/000367809. Epub 2014 Nov 4. Oncology. 2015. PMID: 25377648

6

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.

Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S. Serpico D, et al. Among authors: de braud f. Clin Transl Oncol. 2015 Jul;17(7):530-8. doi: 10.1007/s12094-015-1274-2. Epub 2015 Jan 21. Clin Transl Oncol. 2015. PMID: 25604128

7

Prognosis of women with early breast cancer and PIK3CA mutations.

Di Cosimo S, Bianchi GV, Bregni G, de Braud F. Di Cosimo S, et al. Among authors: de braud f. Breast. 2015 Jun;24(3):283-4. doi: 10.1016/j.breast.2015.02.028. Epub 2015 Mar 12. Breast. 2015. PMID: 25772325 No abstract available.

8

Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma.

Zanardi E, Verzoni E, Grassi P, Necchi A, Giannatempo P, Raggi D, De Braud F, Procopio G. Zanardi E, et al. Among authors: de braud f. Ther Adv Urol. 2015 Jun;7(3):152-61. doi: 10.1177/1756287215574457. Ther Adv Urol. 2015. PMID: 26161146 Free PMC article. Review.

9

Trastuzumab cardiac toxicity: a problem we put our heart into.

Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S. Bregni G, et al. Among authors: de braud f. Tumori. 2016 Jan-Feb;102(1):1-5. doi: 10.5301/tj.5000393. Epub 2015 Jul 30. Tumori. 2016. PMID: 26350178 Review.

10

Better Together: Targeted Combination Therapies in Breast Cancer.

Zanardi E, Bregni G, de Braud F, Di Cosimo S. Zanardi E, et al. Among authors: de braud f. Semin Oncol. 2015 Dec;42(6):887-95. doi: 10.1053/j.seminoncol.2015.09.029. Epub 2015 Sep 24. Semin Oncol. 2015. PMID: 26615133 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

673 results

Search Page